Retrophin, Inc. (NASDAQ:RTRX) has scheduled a conference call for 5th November 2020 at 4:30 PM Eastern Time to announce its 3Q20 financial results.
The conference call will also be webcast live under the investor relations section of the website www.retrophin.com
Earnings Expectation
Retrophin, Inc. is set to announce third quarter earning results on Thursday 5th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, RTRX to report 3Q20 loss of $ 0.52 per share. For the full year, analysts anticipate top line of $ 192.03 million, while looking forward to loss of $ 1.75 per share bottom line.
Retrophin, Inc., a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The companys product candidates also consist of Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; CNSA-001, an orally bioavailable proprietary form of sepiapterin that is in phase II clinical trial for the treatment of phenylketonuria; and liquid ursodeoxycholic acid, a liquid formulation of ursodeoxycholic acid for the treatment of primary biliary cholangitis.
